Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

INTRODUCTION: Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). METHODS: A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for 12 weeks on primary safety and pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagan, Fernando L., Torres‐Yaghi, Yasar, Hebron, Michaeline L., Wilmarth, Barbara, Turner, R. Scott, Matar, Sara, Ferrante, Dalila, Ahn, Jaeil, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157583/
https://www.ncbi.nlm.nih.gov/pubmed/35662832
http://dx.doi.org/10.1002/trc2.12296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157583/
https://www.ncbi.nlm.nih.gov/pubmed/35662832
http://dx.doi.org/10.1002/trc2.12296

Ejemplares similares